NDA 021529 · Organon
Implanon
Etonogestrel · Implantation · Progestin
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jul 17, 2006
Approved uses
3
Original approval plus efficacy supplements
Registered trials
90
14 Phase 3, 5 recruiting
FAERS reports
57,570
13,734 serious, 110 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION and REMOVAL Improper insertion of NEXPLANON increases the risk of complications [see Warnings and Precautions (5.1) ] . Proper training prior to first use of NEXPLANON can minimize the risk of improper NEXPLANON insertion [see Warnings and Precautions (5.1) ] . Because of the risk of complications due to improper insertion and removal NEXPLANON is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the NEXPLANON REMS [see Warnings and Precautions (5.2) ] . WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION and REMOVAL Improper insertion of NEXPLANON increases the risk of complications [see Warnings and Precautions (5.1) ] . Proper training prior to first use of NEXPLANON can minimize the risk of improper NEXPLANON insertion [see Warnings and Precautions (5.1) ] ....
What it is approved for
From the label in effect May 28, 2026.
NEXPLANON ® is indicated for prevention of pregnancy in women of reproductive potential for up to 5 years. NEXPLANON is a progestin indicated for prevention of pregnancy in women of reproductive potential for up to 5 years. ( 1 )
Mechanism: The contraceptive effect of NEXPLANON is achieved by suppression of ovulation, increased viscosity of the cervical mucus, and alterations in the endometrium.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 16, 2026 Supplement 27 · Efficacy LabelLetter
- May 13, 2011 Supplement 7 · Efficacy LetterReviewLabel
- Jul 17, 2006 Original approval · Type 3 - New Dosage Form LabelReviewLetter
2 products under this application
- IMPLANON · ETONOGESTREL 68MG/IMPLANT · IMPLANT, IMPLANTATION · Discontinued
- NEXPLANON · ETONOGESTREL 68MG/IMPLANT · IMPLANT, IMPLANTATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Etonogestrel" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)Pivotal-lookingTerminated
Organon and CoIndustry
NCT02616146 · 2,016 participants · Start Dec 1, 2015 · Primary completion Oct 6, 2016
Drug: ENG-E2 125 μg/300 μg vaginal ring; LNG-EE 150 μg/30 μg COC · For: Contraception
Sites: Vienna, Austria; San José, Costa Rica; Glostrup Municipality, Denmark · 14 sites in all
- Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)Pivotal-lookingTerminated
Organon and CoIndustry
NCT02524288 · 1,941 participants · Start Aug 31, 2015 · Primary completion Sep 16, 2016
Drug: ENG-E2 125 μg/300 μg vaginal ring · For: Contraception
- A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01277211 · 983 participants · Start Sep 19, 2011 · Primary completion Sep 18, 2013
Drug: ENG 120 µg + EE 15 µg intravaginal ring; DRSP 3 mg + EE 30 µg · For: Contraception
- Long-Acting Reversible ContraceptionPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT01299116 · 916 participants · Start Dec 2011 · Primary completion Jun 2016
Drug: DMPA; oral contraceptives and 3 more · For: Contraception
Sites: Chapel Hill, North Carolina
- Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs PlaceboPivotal-lookingRecruiting
Lori GawronAcademic, hospital or other
NCT06162611 · 790 participants (planned) · Start Nov 6, 2023 · Primary completion Apr 30, 2028
Drug: Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg · For: Emergency Contraception
Sites: Salt Lake City, Utah
- LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate StudyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01397097 · 766 participants · Start Sep 2011 · Primary completion Jun 2013
Drug: LNG-IUS (BAY 86-5028); 68 mg etonorgestrel implant for subdermal use (Nexplanon) · For: Contraception
Sites: Ashfield, Australia; Sydney, Australia; North Adelaide, Australia · 43 sites in all
- Kuwa Free! - Live Free!Pivotal-lookingRecruiting
University of Alabama at BirminghamAcademic, hospital or other
NCT05044962 · 700 participants (planned) · Start Nov 26, 2021 · Primary completion Mar 31, 2027
Drug: Cabotegravir/ Rilpivirine; Etonogestrel (ETG) implant and 3 more · For: HIV Infections; Contraception; Drug-drug Interaction
Sites: Eldoret, Kenya
- A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01709318 · 666 participants · Start Dec 12, 2012 · Primary completion Oct 22, 2013
Drug: Nomegestrol acetate (NOMAC); Etonogestrel (ENG) and 2 more · For: Contraception
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event12,139
- product quality issue6,915
- complication associated with device6,622
- device breakage5,381
- incorrect product administration duration5,033
- complication of device insertion4,758
- device difficult to use4,584
- complication of device removal4,373
- unintended pregnancy3,743
- device deployment issue3,686
- pregnancy with implant contraceptive3,434
- vaginal haemorrhage3,434
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 34 |
| 2007 | 88 |
| 2008 | 56 |
| 2009 | 56 |
| 2010 | 3 |
| 2011 | 55 |
| 2012 | 619 |
| 2013 | 2,766 |
| 2014 | 3,778 |
| 2015 | 4,243 |
| 2016 | 4,828 |
| 2017 | 4,427 |
| 2018 | 4,941 |
| 2019 | 4,845 |
| 2020 | 3,976 |
| 2021 | 3,817 |
| 2022 | 3,505 |
| 2023 | 1,626 |
| 2024 | 1,477 |
| 2025 | 1,819 |
| 2026 | 10,610 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nexplanon (Etonogestrel)
2024 spending
$455K
Beneficiaries
392
393 claims
Per beneficiary
$1,162
$1,158.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $66,788 |
| 2022 | $273,157 |
| 2023 | $401,524 |
| 2024 | $455,380 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant.
Moray KV, Chaurasia H, Sachin O, et al. · Reprod Health 2021 · Meta-Analysis, Systematic Review
- Locating Hormone-Releasing Contraceptive Implants Using Near-Infrared Light.
Akturk HK · Obstet Gynecol 2021 · Clinical Trial
- Progestagens for pain symptoms associated with endometriosis.
Chen I, Kives S, Zakhari A, et al. · Cochrane Database Syst Rev 2025 · Systematic Review, Meta-Analysis
- Norethisterone for prolonged uterine bleeding associated with etonogestrel implant (IMPLANET): a randomized controlled trial.
Andrade MCR, Yamaguti EMM, de Nadai MN, et al. · Am J Obstet Gynecol 2026 · Randomized Controlled Trial, Multicenter Study
- Steroid hormones for contraception in men.
Grimes DA, Lopez LM, Gallo MF, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, N.I.H., Extramural
- Steroid hormones for contraception in men.
Grimes DA, Lopez LM, Gallo MF, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
Sponsor: Organon · Also marketed as Nexplanon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.